C
TVTX icon

Covestor’s Travere Therapeutics TVTX Stock Holding History

Covestor’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Buy
21
+15
+250% +$665 ﹤0.01% 2358
2026
Q1 		$0 Hold
6
– – ﹤0.01% 2782
2025
Q4 		$0 Hold
6
– – ﹤0.01% 2749
2025
Q3 		$0 Hold
6
– – ﹤0.01% 2789
2025
Q2 		$0 Sell
6
-1
-14% -$17 ﹤0.01% 2771
2025
Q1 		$0 Hold
7
– – ﹤0.01% 2742
2024
Q4 		$0 Sell
7
-4
-36% -$71 ﹤0.01% 2753
2024
Q3 		$0 Hold
11
– – ﹤0.01% 2783
2024
Q2 		$0 Sell
11
-1
-8% -$7 ﹤0.01% 2773
2024
Q1 		$0 Hold
12
– – ﹤0.01% 2758
2023
Q4 		$0 Buy
12
+5
+71% +$36 ﹤0.01% 2733
2023
Q3 		$0 Sell
7
-1
-13% -$14 ﹤0.01% 2730
2023
Q2 		$0 Sell
8
-1
-11% -$18 ﹤0.01% 2669
2023
Q1 		$0 Hold
9
– – ﹤0.01% 2603
2022
Q4 		$0 Hold
9
– – ﹤0.01% 2623
2022
Q3 		$0 Sell
9
-2
-18% -$52 ﹤0.01% 2624
2022
Q2 		$0 Sell
11
-3
-21% -$75 ﹤0.01% 2376
2022
Q1 		$0 Sell
14
-3
-18% -$80 ﹤0.01% 2450
2021
Q4 		$1K Buy
+17
New +$479 ﹤0.01% 1963

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Covestor's TVTX Position: Q2 2026 in Review

Covestor increased its Travere Therapeutics (TVTX) stake by 250% in Q2 2026, buying an estimated $665 and bringing the position to 21 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2358.

Covestor first reported a position in TVTX in Q4 2021 and has held it in 19 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Covestor held 21 shares of Travere Therapeutics worth $1K as of Q2 2026.
  • Covestor bought 15 Travere Therapeutics shares in Q2 2026, an estimated $665.
  • Travere Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2358 holding.
  • Covestor first reported a position in Travere Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.